International Journal of Advanced Research in Medicine
2020, Vol. 2, Issue 2, Part C
Comparative study of acute ischemic stroke in Indian patients on dual anti-platelet therapy clopidogrel and aspirin versus aspirin using modified ranking scale
Author(s): Dr. Nagendra S and Dr. Dayananda AS
Abstract:Background: Stroke is a major cause of morbidity and mortality in an aging population. In the elderly, ischemic stroke accounts for more than 80% of all stroke cases. Stroke is the second leading cause of disability after ischaemic heart disease (IHD) and is the sixth leading cause worldwide. The aim of this study was to evaluate the effects of clopidogrel and aspirin (combination therapy) and aspirin alone (monotherapy for Acute Ischemic Stroke patients.
Material and Methods: This isaProspective, non-randomized and observational study conducted in the Department of General Medicine, Subbaiah Institute of Medical Sciences, Shimoga among 70 acute ischemic stroke patients from January 2019 to September 2019. Clopidogrel at an initial dose of 300 mg, followed by 75 mg per day for 90 days, plus aspirin at a dose of 75 mg per day for the first 21 days) or aspirin (75 mg per day for 90 days) group.
Result: In our study, majority of patients were more than 60 years and least were less than 40 years in both the groups. Predominant were male than female in both the groups. An mRS of 3–6 at 90-day assessment occurred in 3 patients in the clopidogrel-aspirin group, and in 3 patients in the aspirin group (p=0.039). Poor quality of life at 90 days occurred in 1 patients in the clopidogrel aspirin group and in 2 in the aspirin group (p=0.081).
Conclusions: For patients with acute Acute Ischemic Stroke, treatment with clopidogrel and aspirin provided significantly greater inhibition of platelet activity than aspirin alone. Thus, dual therapy can be safer and more effective in reducing ischemic stroke recurrence.
Dr. Nagendra S, Dr. Dayananda AS. Comparative study of acute ischemic stroke in Indian patients on dual anti-platelet therapy clopidogrel and aspirin versus aspirin using modified ranking scale. Int J Adv Res Med 2020;2(2):198-201. DOI: 10.22271/27069567.2020.v2.i2c.87